|
|
Articles
by
Luisella Bocchio- Chiavetto |
Total Records (
2 ) for
Luisella Bocchio- Chiavetto |
|
 |
|
|
|
Niklas Mattsson
,
Ulf Andreasson
,
Staffan Persson
,
Hiroyuki Arai
,
Sat Dev Batish
,
Sergio Bernardini
,
Luisella Bocchio- Chiavetto
,
Marinus A. Blankenstein
,
Maria C. Carrillo
,
Sonia Chalbot
,
Els Coart
,
Davide Chiasserini
,
Neal Cutler
,
Gunilla Dahlfors
,
Stefan Duller
,
Anne M. Fagan
,
Orestes Forlenza
,
Giovanni B. Frisoni
,
Douglas Galasko
,
Daniela Galimberti
,
Harald Hampel
,
Aase Handberg
,
Michael T. Heneka
,
Adrianna Z. Herskovits
,
Sanna-Kaisa Herukka
,
David M. Holtzman
,
Christian Humpel
,
Bradley T. Hyman
,
Khalid Iqbal
,
Khalid Iqbal
,
Stephan A. Kaeser
,
Elmar Kaiser
,
Elisabeth Kapaki
,
Daniel Kidd
,
Peter Klivenyi
,
Cindy S. Knudsen
,
Markus P. Kummer
,
James Lui
,
Albert Llado
,
Piotr Lewczuk
,
Qiao-Xin Li
,
Ralph Martins
,
Colin Masters
,
John McAuliffe
,
Marc Mercken
,
Abhay Moghekar
,
Jose Luis Molinuevo
,
Thomas J. Montine
,
William Nowatzke
,
Richard O’Brien
,
Markus Otto
,
George P. Paraskevas
,
Lucilla Parnetti
,
Ronald C. Petersen
,
David Prvulovic
,
Herman P.M. de Reus
,
Robert A. Rissman
,
Elio Scarpini
,
Alessandro Stefani
,
Hilkka Soininen
,
Johannes Schroder
,
Leslie M. Shaw
,
Anders Skinningsrud
,
Brith Skrogstad
and
Annette Spreer
|
|
Background
The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimers disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimers Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program.
Methods
The program is open for laboratories using commercially available kits for Aβ, T-tau, or P-tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Molndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples.
Results
Forty laboratories participated. Twenty-six used INNOTEST enzyme-linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO-BIA AlzBio3 kit (both measure Aβ-(1-42), P-tau(181P), and T-tau), and 5 used Meso Scale Discovery with the Aβ triplex (AβN-42, AβN-40, and AβN-38) or T-tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within-laboratory precisions differed considerably between biomarkers within individual laboratories.
Conclusions
Measurements of CSF AD biomarkers show large between-laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers. |
|
|
|
|
Donata Paternico
,
Samantha Galluzzi
,
Valeria Drago
,
Luisella Bocchio- Chiavetto
,
Roberta Zanardini
,
Laura Pedrini
,
Manuela Baronio
,
Giovanni Amicucci
and
Giovanni B. Frisoni
|
|
Background
Low amyloid β42 (Aβ42) and high total tau and phosphorylated tau (p-tau) concentrations in the cerebrospinal fluid (CSF) are biomarkers of Alzheimers disease (AD), reflecting brain deposition of amyloid plaques and tangles. Age and apolipoprotein E allele E4 are two strong risk factors for AD, but few data are still available on their effect on CSF markers in normal aging.
Objective
To study the effect of age on CSF Aβ42, total tau, and p-tau levels in a well-characterized group of cognitively normal subjects.
Methods
CSF Aβ42 levels of 81 subjects (27% female, 53 ± 15.3 years, range: 2188) were determined with sandwich enzyme-linked immunosorbent assay; of these, total tau and p-tau levels were measured in 61 (75%) and 42 (52%) cases, respectively. A linear regression analysis between age and CSF markers was carried out on the whole sample and separately in apolipoprotein E allele ɛ4 carriers and noncarriers.
Results
The median levels of all markers were significantly different between young (<65 years) and old (≥65 years) subjects (Aβ42: P = .03; tau: P = .02; p-tau: P = .002; tau/Aβ42: P = .004; p-tau/Aβ42: P = .03). The association of marker levels with age was confirmed in linear regression models, where a positive relationship with age was observed for total tau (B = 2.3; 95% confidence interval [CI]: 0.89 to 3.7; P = .002), p-tau (B = 0.5; 95% CI: 0.1 to 0.9; P = .02), and tau/Aβ42 ratio (B = 0.006; 95% CI: 0.002 to 0.01; P = .002). No subjects showed abnormal tau, whereas 19% showed abnormal CSF Aβ42 concentrations.
Conclusion
In cognitively normal subjects, the concentrations of CSF biomarkers of AD are associated with age. Further longitudinal studies could clarify whether Aβ42 low levels represent a preclinical AD biomarker. |
|
|
|
|
|
|